1 September 2020
1 September 2020
P.U. (A) 257

WARTA KERAJAAN PERSEKUTUAN

FEDERAL GOVERNMENT GAZETTE

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020

POISONS (AMENDMENT OF POISONS LIST) ORDER 2020

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2020**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

(i) dengan memotong butiran "Abciximab" dan butir-butir yang berhubungan dengannya;

(ii) dengan memasukkan selepas butiran "Abatacept" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Abemaciclib	-	All preparations";				

(iii) dengan memotong butiran "Adalimumab" dan butir-butir yang berhubungan dengannya;

(iv) dengan memasukkan selepas butiran "Alcuronium chloride" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Alectinib	-	All preparations";				

(v) dengan memotong butiran "Alemtuzumab" dan butir-butir yang berhubungan dengannya;

(vi) dengan memotong butiran "Alirocumab" dan butir-butir yang berhubungan dengannya;

(vii) dengan menggantikan butiran "Allergens (in test kits)" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Allergens	-	(1) All preparations for therapeutic use (2) In-vivo diagnostic test kits	-	-	-	(1) All preparations unless in Group B (2) Preparation for laboratory use";

(viii) di bawah "Antihistamines; the following:", dengan memasukkan selepas butiran "Cyproheptadine" butiran "Desloratadine";

(ix) dengan memasukkan selepas butiran "Antimony; its chlorides, oxides, sulphides, antimonates, antimonites; organic compounds of antimony" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Apalutamide	-	All preparations";				

(x) dengan memotong butiran "Atezolizumab" dan butir-butir yang berhubungan dengannya;

(xi) dengan memasukkan selepas butiran "Baclofen; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Name	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Baloxavir marboxil	-	All preparations";				

(xii) dengan memasukkan selepas butiran "Barbituric acid and other substances structurally derived therefrom; their compounds; their salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Baricitinib	-	All preparations";				

(xiii) dengan memotong butiran "Basiliximab" dan butir-butir yang berhubungan dengannya;

(xiv) dengan memasukkan selepas butiran "Beclamide" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Bedaquiline	-	All preparations";				

(xv) dengan memotong butiran "Belimumab" dan butir-butir yang berhubungan dengannya;

(xvi) dengan memotong butiran "Bevacizumab" dan butir-butir yang berhubungan dengannya;

(xvii) dengan memotong butiran "Blinatumomab" dan butir-butir yang berhubungan dengannya;

(xviii) dengan memotong butiran "Brentuximab" dan butir-butir yang berhubungan dengannya;

(xix) dengan memasukkan selepas butiran "Brexpiprazole" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Brigatinib	-	All preparations";				

(xx) dengan memotong butiran "Canakinumab" dan butir-butir yang berhubungan dengannya;

(xxi) dengan memasukkan selepas butiran "Carfilzomib" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Cariprazine	-	All preparations";				

(xxii) dengan memotong butiran "Certolizumab" dan butir-butir yang berhubungan dengannya;

(xxiii) dengan memotong butiran "Cetuximab" dan butir-butir yang berhubungan dengannya;

(xxiv) dengan memasukkan selepas butiran "Chloroform" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"4-Chloromethcathinone	-	All preparations";				

(xxv) dengan menggantikan butiran "Citicoline" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Citicoline	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B
Cladribine	-	All preparations";				

(xxvi) dengan memasukkan selepas butiran "Clozapine" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Cobicistat	-	All preparations";				

(xxvii) dengan memotong butiran "Dacliximab" dan butir-butir yang berhubungan dengannya;

(xxviii) dengan memotong butiran "Daratumumab" dan butir-butir yang berhubungan dengannya;

(xxix) dengan memotong butiran "Denosumab" dan butir-butir yang berhubungan dengannya;

(xxx) dengan memasukkan selepas butiran "Dimethyl fumarate" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Dimethylone	-	All preparations";				

(xxxi) dengan memotong butiran "Efalizumab" dan butir-butir yang berhubungan dengannya;

(xxxii) dengan memasukkan selepas butiran "Eltrombopag" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Elvitegravir	-	All preparations";				

(xxxiii) dengan memasukkan selepas butiran "Eptifibatide" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Erdosteine	-	-	All preparations";			

(xxxiv) dengan memasukkan selepas butiran "Ertapenem sodium" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ertugliflozin	-	All preparations";				

(xxxv) dengan memasukkan selepas butiran "Etanercept" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Etelcalcetide	-	All preparations";				

(xxxvi) dengan memotong butiran "Evolocumab" dan butir-butir yang berhubungan dengannya;

(xxxvii) dengan memasukkan selepas butiran "4-Fluoroamphetamine (4-FA) (DD)" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"3-Fluoromethcathinone	-	All preparations";				

(xxxviii) dengan memasukkan selepas butiran "Fluoxetine; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Fluralaner	-	All preparations";				

(xxxix) dengan memasukkan selepas butiran "Glaphenine" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Glecaprevir	-	All preparations";				

(xl) dengan memasukkan selepas butiran "Glucose" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Glutathione	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(xli) dengan memotong butiran "Golimumab" dan butir-butir yang berhubungan dengannya;

(xlii) dengan memotong butiran "Idarucizumab" dan butir-butir yang berhubungan dengannya;

(xliii) dengan memotong butiran "Infliximab" dan butir-butir yang berhubungan dengannya;

(xliv) dengan memasukkan selepas butiran "Iomeprol" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Iopamidol	-	All preparations";				

(xlv) dengan memasukkan selepas butiran "Irinotecan; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Isavuconazole	-	All preparations";				

(xlvi) dengan memasukkan selepas butiran "Ivermectin" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ixazomib	-	All preparations";				

(xlvii) dengan memasukkan selepas butiran "Leptazol" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lercanidipine	-	All preparations				
Letermovir	-	All preparations";				

(xlviii) dengan memasukkan selepas butiran "Liraglutide" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lisdexamfetamine	-	All preparations";				

(xlix) dengan menggantikan butiran "Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:" serta butiran di bawahnya dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:	All preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use (2) Suppositories, lozenges and pastilles (3) Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic	Preparations for laboratory use";		

Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts

Benzocaine

Bupivacaine

Butyl aminobenzoate

Cinchocaine

Diperodon

Etidocaine

Lignocaine

Levobupivacaine

Mepivacaine

Orthocaine

Oxethazaine

Phenacaine

Phenodianisyl

Prilocaine

Ropivacaine

Tetracaine

(l) dengan memasukkan selepas butiran "Lonazolac; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lonoctocog alfa	-	All preparations";				

(li) dengan memasukkan selepas butiran "Lopinavir" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lorlatinib	-	All preparations";				

(lii) dengan memasukkan selepas butiran "Lovastatin" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lubiprostone	-	All preparations";				

(liii) dengan memasukkan selepas butiran "10-Methoxydeserpidine" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"5-Methoxy-N,N-diisopropyltryptamine	-	All preparations";				

(liv) dengan memasukkan selepas butiran "5-Methoxy-3, 4 methylenedioxyamphetamine (MMDA) (DD)" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"5-Methoxy-N,N-methylisopropyltryptamine	-	All preparations				
2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)	-	All preparations				
4-Methyl-alpha-pyrrolidinobutiophenone	-	All preparations";				

(lv) dengan memasukkan selepas butiran "Methyl bromide" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"4-Methylbuphedrone	-	All preparations";				

(lvi) dengan memasukkan selepas butiran "Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-methylbutanoate (5F-AMB)" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)	-	All preparations";				

(lvii) dengan memasukkan selepas butiran "Moclobemide" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Modafinil	-	All preparations";				

(lviii) dengan memasukkan selepas butiran "Monensin" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Monoclonal antibody; includes the followings:	-	All preparations";				
Abciximab						
Adalimumab						
Alemtuzumab						
Alirocumab						

Atezolizumab

Basiliximab

Belimumab

Benralizumab

Bevacizumab

Blinatumomab

Brentuximab

Brodalumab

Canakinumab

Certolizumab

Cetuximab

Dacliximab

Daratumumab

Denosumab

Efalizumab

Emicizumab

Erenumab

Evolocumab

Golimumab

Guselkumab

Idarucizumab

Infliximab

Ixekizumab

Mepolizumab

Natalizumab

Necitumumab

Nivolumab

Obinutuzumab

Ofatumumab

Omalizumab

Palivizumab

Panitumumab

Pembrolizumab

Pertuzumab

Ramucirumab

Ranibizumab

Risankizumab

Rituximab

Sarilumab

Secukinumab

Tocilizumab

Trastuzumab

Ustekinumab

Vedolizumab

(lix) dengan menggantikan butiran “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers -” dengan butiran “Narcotic substances; the following:";

(lx) dengan memotong butiran “Natalizumab” dan butir-butir yang berhubung dengannya;

(lxi) dengan memotong butiran “Necitumumab” dan butir-butir yang berhubung dengannya;

(lxii) dengan memasukkan selepas butiran “Nepafenac” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
“Neratinib	-	All preparations”;				

(lxiii) dengan menggantikan butiran "Nitric Oxide" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Nitric Oxide	-	Preparations in the form of medicinal gas for therapeutic use	-	-	-	All preparations unless in Group B";

(lxiv) dengan memotong butiran "Nivolumab" dan butir-butir yang berhubung dengannya;

(lxv) dengan memotong butiran"Obinutuzumab" dan butir-butir yang berhubung dengannya;

(lxvi) dengan memotong butiran "Ofatumumab" dan butir-butir yang berhubung dengannya;

(lxvii) dengan memotong butiran "Omalizumab"dan butir-butir yang berhubung dengannya;

(lxviii) dengan memotong butiran "Palivizumab" butir-butir yang berhubung dengannya;

(lxix) dengan memotong butiran "Panitumumab" butir-butir yang berhubung dengannya;

(lxx) dengan memotong butiran“Pembrolizumab” butir-butir yang berhubung dengannya;

(lxxi) dengan memotong butiran “Pertuzumab” butir-butir yang berhubung dengannya;

(lxxii) dengan menggantikan butiran “Phenytoin and other substances structurally derived from hydantoin; their salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
“Phenytoin and other substances structurally derived from hydantoin; their salts	-	All preparations unless exempted	-	-	-	Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984 containing derivatives of hydantoin”;

(lxxiii) dengan memasukkan selepas butiran “Phosphorus white, yellow, red or black” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Pibrentasvir	-	All preparations";				

(lxxiv) dengan memotong butiran "Ramucirumab" dan butir-butir yang berhubung dengannya;

(lxxv) dengan memotong butiran "Ranibizumab" dan butir-butir yang berhubung dengannya;

(lxxvi) dengan memasukkan selepas butiran "Ribavirin" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ribociclib	-	All preparations";				

(lxxvii) dengan memasukkan selepas butiran "Riociguat" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
“Ripasudil	-	All preparations”;				

(lxxviii) dengan memotong butiran “Rituximab” dan butir-butir yang berhubung dengannya;

(lxxix) dengan memotong butiran “Secukinumab” dan butir-butir yang berhubung dengannya;

(lxxx) dengan memasukkan selepas butiran “Selexipag” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Semaglutide	-	All preparations				
“Semduramicin	-	All preparations”;				

(lxxxi) dengan menggantikan butiran “Sildenafil; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Sildenafil	-	All preparations				
Siltuximab	-	All preparations";				

(lxxxii) dengan memasukkan selepas butiran "Simeprevir" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Simoctocog alfa	-	All preparations";				

(lxxxiii) dengan memasukkan selepas butiran "Tadalafil" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Tafluprost	-	All preparations";				

(lxxxiv) dengan memotong butiran "Tocilizumab" dan butir-butir yang berhubung dengannya;

(lxxxv) dengan memotong butiran "Trastuzumab" dan butir-butir yang berhubung dengannya;

(lxxxvi) dengan memasukkan selepas butiran "2, 2, 2-Trichloroethanol; esters of; their salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"3-Trifluoromethylphenylpiperazine (TFMPP)	-	All preparations";				

(lxxxvii) dengan memasukkan selepas butiran "Trioxsalen" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Triptorelin	-	All preparations";				

(lxxxviii) dengan memasukkan selepas butiran "Udenafil" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ulinastatin	-	All preparations unless exempted	-	-	-	Naturally occurring ulinastatin";

(lxxxix) dengan memotong butiran "Ustekinumab" dan butir-butir yang berhubung dengannya;

(xc) dengan memasukkan selepas butiran "Vecuronium; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Velpatasvir	-	All preparations";				

(xci) dengan memotong butiran "Vedolizumab" dan butir-butir yang berhubung dengannya;

(xcii) dengan memasukkan selepas butiran "Vemurafenib" dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Venetoclax	-	All preparations"; dan				

(xciii) dengan memotong butiran "Zacyclonol; its salts" dan butir-butir yang berhubung dengannya; dan

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai **"Analeptics and Central Stimulants:"** —

(A) dengan memasukkan selepas butiran "Cathinone (DD)" butiran "4-Chloromethcathinone";

(B) dengan memasukkan selepas butiran "2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)" butiran "Dimethylone";

(C) dengan memasukkan selepas butiran "Fluoroamphetamine (4-FA) (DD)" butiran "3-Fluoromethcathinone";

(D) dengan memasukkan selepas butiran "Leptazol" butiran "Lisdexamfetamine";

(E) dengan memasukkan selepas butiran "Methiopropamine (MPA)" butiran "5-Methoxy-N,N-diisopropyltryptamine";

(F) dengan memasukkan selepas butiran "5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD)" butiran berikut:
"5-Methoxy-N,N-methylisopropyltryptamine
4-Methyl-alpha-pyrrolidinobutiophenone
4-Methylbuphedrone";

(G) dengan memasukkan selepas butiran "4-Methylethcathinone (4-MEC)" butiran "Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)";

(H) dengan memasukkan selepas butiran "N-methyl-1-(3, 4-methylenedioxyphenyl)-2-butanamide (DD)" butiran "Modafinil"; dan

(I) dengan memasukkan selepas butiran "Strychnine" butiran "3-Trifluoromethylphenylpiperazine (TFMPP)";

(ii) dalam senarai **"Analgesics including antipyretic and anti-inflammatory agents:"—**

(A) dengan memasukkan selepas butiran "Enphenamic acid; its salts" butiran "Erenumab"; dan

(B) dengan memasukkan selepas butiran "Mesalazine" butiran "2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)";

(iii) dalam senarai "**Anti-asthmatics:**",—

(A) dengan memasukkan selepas butiran "Bambuterol" butiran "Benralizumab"; dan

(B) dengan memasukkan selepas butiran "Indacaterol" butiran "Mepolizumab";

(iv) dalam senarai **"Antidiabetics:" —**

(A) dengan memasukkan selepas butiran "Empagliflozin" butiran "Ertugliflozin"; dan

(B) dengan memasukkan selepas butiran "Saxagliptin" butiran "Semaglutide";

(v) dalam senarai "**Antifungals and Antiprotozoals:**"—

(A) dengan memasukkan selepas butiran "Imidocarb" butiran "Isavuconazole"; dan

(B) dengan memasukkan selepas butiran "Secnidazole" butiran "Semduramicin";

(vi) dalam senarai "**Antihistamines:**", dengan memasukkan selepas butiran "Cyproheptadine" butiran "Desloratadine";

(vii) dalam senarai "**Antihypertensives:**", dengan memasukkan selepas butiran "Lacidipine" butiran "Lercanidipine";

(viii) dalam senarai "**Antineoplastic agents and Immunosuppressants:**"—

(A) dengan memasukkan selepas butiran "Abatacept" butiran "Abemaciclib";

(B) dengan memasukkan selepas butiran "Afatinib" butiran "Alectinib";

(C) dengan memasukkan selepas butiran "Anastrozole" butiran "Apalutamide";

(D) dengan memasukkan selepas butiran "Azathioprine; its salts" butiran "Baricitinib";

(E) dengan memasukkan selepas butiran "Brentuximab" butiran berikut:

"Brigatinib

Brodalumab";

(F) dengan memasukkan selepas butiran "Cisplatin" butiran "Cladribine";

(G) dengan memasukkan selepas butiran "Gemcitabine, its salts" butiran "Guselkumab";

(H) dengan memasukkan selepas butiran "Irinotecan; its salts " butiran berikut:

"Ixazomib

Ixekizumab";

(I) dengan memasukkan selepas butiran "Lomustine; its salts" butiran "Lorlatinib";

(J) dengan memasukkan selepas butiran "Necitumumab" butiran "Neratinib";

(K) dengan memasukkan selepas butiran "Regorafenib" butiran berikut:

"Ribociclib

Risankizumab";

(L) dengan memasukkan selepas butiran "Ruxolitinib" butiran "Sarilumab";

(M) dengan memasukkan selepas butiran "Semustine; its salts" butiran "Siltuximab";

(N) dengan memasukkan selepas butiran "Trimetrexate" butiran "Triptorelin"; dan

(O) dengan memasukkan selepas butiran "Vemurafenib" butiran "Venetoclax";

(ix) dalam senarai "**Antitubercular agents:**", dengan memasukkan selepas butiran "p-Aminosalicyclic acid and other substances structurally derived therefrom; their salts; their esters" butiran "Bedaquiline";

(x) dalam senarai "**Antiviral agents:**"—

(A) dengan memasukkan selepas butiran "Atazanavir" butiran "Baloxavir marboxil";

(B) dengan memasukkan selepas butiran "Elbasvir" butiran "Elvitegravir";

(C) dengan memasukkan selepas butiran "Ganciclovir" butiran "Glecaprevir";

(D) dengan memasukkan selepas butiran "Ledipasvir" butiran "Letermovir";

(E) dengan memasukkan selepas butiran "Penciclovir" butiran "Pibrentasvir"; dan

(F) dengan memasukkan selepas butiran "Valaciclovir; its salts" butiran "Velpatasvir";

(xi) dalam senarai "**Hormones:**", dengan memotong butiran " Zacyclonol; its salts";

(xii) dalam senarai "**Narcotics**", dengan menggantikan butiran "Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); salts of their esters and ethers:" dengan butiran "Narcotis substances; the followings:";

(xiii) dalam senarai "**Tranquillisers:**", dengan memasukkan selepas butiran "Captodiamine; its salts" butiran "Cariprazine";

(xiv) dalam senarai "**Vasolidators:**", dengan menggantikan butiran " Sildenafil; its salts" dengan butiran "Sildenafil"; dan

(xv) dalam senarai "**Miscellaneous:**"—

(A) dengan memasukkan selepas butiran "Clopidogrel" butiran "Cobicistat";

(B) dengan memasukkan selepas butiran "Eltrombopag" butiran "Emicizumab";

(C) dengan memasukkan selepas butiran "Eptifibatide" butiran "Erdosteine";

(D) dengan memasukkan selepas butiran "Ergot, alkaloids of" butiran "Etelcalcetide";

(E) dengan memasukkan selepas butiran "Fluorides, alkali; organofluorides" butiran "Fluralaner";

(F) dengan memasukkan selepas butiran "Glucose" butiran "Glutathione";

(G) dengan memasukkan selepas butiran "Iomeprol" butiran "Iopamidol";

(H) dengan memasukkan selepas butiran "Lodoxamide tromethamine" butiran "Lonoctocog alfa";

(I) dengan memasukkan selepas butiran "Lovastatin" butiran "Lubiprostone"

(J) dengan memasukkan selepas butiran "Rimonabant" butiran "Ripasudil";

(K) dengan memasukkan selepas butiran "Silodosin" dengan butiran "Simoctocog alfa";

(L) dengan memasukkan selepas butiran "Sumatriptan" butiran "Tafluprost"; dan

(M) dengan memasukkan selepas butiran "L-Tryptophan" butiran "Ulinastatin".

Dibuat 7 Ogos 2020
[KKM.R.600-1/1/56; PN(PU2)172/XVIII]

DATO' SRI DR. ADHAM BIN BABA
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2020

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2020**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule —

(a) in the Poison List—

(i) by deleting the item "Abciximab" and the particulars relating to it;

(ii) by inserting after the item "Abatacept" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Abemaciclib	-	All preparations";				

(iii) by deleting the item "Adalimumab" and the particulars relating to it;

(iv) by inserting after the item "Alcuronium chloride" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Alectinib	-	All preparations";				

(v) by deleting the item "Alemtuzumab" and the particulars relating to it;

(vi) by deleting the item "Alirocumab" and the particulars relating to it;

(vii) by substituting for the item "Allergens (in test kits)" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Allergens	-	(1) All preparations for therapeutic use (2) In-vivo diagnostic test kits	-	-	-	(1) All preparations unless in Group B (2) Preparation for laboratory use";

(viii) under "Antihistamines; the following:", by inserting after the item "Cyproheptadine" the item "Desloratadine":

(ix) by inserting after the item "Antimony; its chlorides, oxides, sulphides, antimonates, antimonites; organic compounds of antimony " and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Apalutamide	-	All preparations";				

(x) by deleting the item "Atezolizumab" and the particulars relating to it;

(xi) by inserting after the item "Baclofen; its salts" and the particulars relating to it the following item:

Name	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Baloxavir marboxil	-	All preparations";				

(xii) by inserting after the item "Barbituric acid and other substances structurally derived therefrom; their compounds; their salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Baricitinib	-	All preparations";				

(xiii) by deleting the item "Basiliximab" and the particulars relating to it;

(xiv) by inserting after the item "Beclamide" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Bedaquiline	-	All preparations";				

(xv) by deleting the item "Belimumab" and the particulars relating to it;

(xvi) by deleting the item "Bevacizumab" and the particulars relating to it;

(xvii) by deleting the item "Blinatumomab" and the particulars relating to it;

(xviii) by deleting the item "Brentuximab" and the particulars relating to it;

(xix) by inserting after the item "Brexpiprazole" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Brigatinib	-	All preparations";				

(xx) by deleting the item "Canakinumab" and the particulars relating to it;

(xxi) by inserting after the item "Carfilzomib" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Cariprazine	-	All preparations";				

(xxii) by deleting the item "Certolizumab" and the particulars relating to it;

(xxiii) by deleting the item "Cetuximab" and the particulars relating to it;

(xxiv) by inserting after the item "Chloroform" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"4-Chloromethcathinone	-	All preparations";				

(xxv) by substituting for the item "Citicoline" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Citicoline	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B
Cladribine	-	All preparations";				

(xxvi) by inserting after the item "Clozapine" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Cobicistat	-	All preparations";				

(xxvii) by deleting the item "Dacliximab" and the particulars relating to it;

(xxviii) by deleting the item "Daratumumab" and the particulars relating to it;

(xxix) by deleting the item "Denosumab" and the particulars relating to it;

(xxx) by inserting after the item "Dimethyl fumarate" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Dimethylone	-	All preparations";				

(xxxi) by deleting the item "Efalizumab" and the particulars relating to it;

(xxxii) by inserting after the item "Eltrombopag" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Elvitegravir	-	All preparations";				

(xxxiii) by inserting after the item "Eptifibatide" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Erdosteine	-	-	All preparations";			

(xxxiv) by inserting after the item "Ertepenem sodium" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ertugliflozin	-	All preparations";				

(xxxv) by inserting after the item "Etanercept" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Etelcalcetide	-	All preparations";				

(xxxvi) by deleting the item "Evolocumab" and the particulars relating to it;

(xxxvii) by inserting after the item "4-Fluoroamphetamine (4-FA) (DD)" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"3-Fluoromethcathinone	-	All preparations";				

(xxxviii) by inserting after the item "Fluoxetine; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Fluralaner	-	All preparations";				

(xxxix) by inserting after the item "Glaphenine" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Glecaprevir	-	All preparations";				

(xl) by inserting after the item "Glucose" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Glutathione	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(xli) by deleting the item "Golimumab" and the particulars relating to it;

(xlii) by deleting the item "Idarucizumab" and the particulars relating to it;

(xliii) by deleting the item "Infliximab" and the particulars relating to it;

(xliv) by inserting after the item "Iomeprol" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Iopamidol	-	All preparations";				

(xlv) by inserting after the item "Irinotecan; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Isavuconazole	-	All preparations";				

(xlvi) by inserting after the item "Ivermectin" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ixazomib	-	All preparations";				

(xlvii) by inserting after the item "Leptazol" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lercanidipine	-	All preparations				
Letermovir	-	All preparations";				

(xlviii) by inserting after the item "Liraglutide" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lisdexamphetamine	-	All preparations";				

(xlix) by substituting for the item "Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:" and the items below it and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:	All preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use	Preparations for laboratory use";		

		(2) Suppositories, lozenges and pastilles
		(3) Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic
Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts		
Benzocaine		

Bupivacaine

Butyl aminobenzoate

Cinchocaine

Diperodon

Etidocaine

Lignocaine

Levobupivacaine

Mepivacaine

Orthocaine

Oxethazaine

Phenacaine

Phenodianisyl

Prilocaine

Ropivacaine

Tetracaine

(l) by inserting after the item "Lonazolac; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lonoctocog alfa	-	All preparations";				

(li) by inserting after the item "Lopinavir" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lorlatinib	-	All preparations";				

(lii) by inserting after the item "Lovastatin" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Lubiprostone	-	All preparations";				

(liii) by inserting after the item "10-Methoxydeserpidine" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"5-Methoxy-N,N-diisopropyltryptamine	-	All preparations";				

(liv) by inserting after the item "5-Methoxy-3, 4 methylenedioxyamphetamine (MMDA) (DD)" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"5-Methoxy-N,N-methylisopropyltryptamine	-	All preparations				
2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)	-	All preparations				
4-Methyl-alpha-pyrrolidinobutiophenone	-	All preparations";				

(lv) by inserting after the item "Methyl bromide" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"4-Methylbuphedrone	-	All preparations";				

(lvi) by inserting after the item "Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-methylbutanoate (5F-AMB)" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)	-	All preparations";				

(lvii) by inserting after the item "Moclobemide" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Modafinil	-	All preparations";				

(lviii) by inserting after the item "Monensin" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Monoclonal antibody; includes the followings:	-	All preparations";				
Abciximab						
Adalimumab						
Alemtuzumab						
Alirocumab						
Atezolizumab						
Basiliximab						
Belimumab						
Benralizumab						

Bevacizumab

Blinatumomab

Brentuximab

Brodalumab

Canakinumab

Certolizumab

Cetuximab

Dacliximab

Daratumumab

Denosumab

Efalizumab

Emicizumab

Erenumab

Evolocumab

Golimumab

Guselkumab

Idarucizumab

Infliximab

Ixekizumab

Mepolizumab

Natalizumab

Necitumumab

Nivolumab

Obinutuzumab

Ofatumumab

Omalizumab

Palivizumab

Panitumumab

Pembrolizumab

Pertuzumab

Ramucirumab

Ranibizumab

Risankizumab

Rituximab

Sarilumab

Secukinumab

Tocilizumab

Trastuzumab

Ustekinumab

Vedolizumab

(lix) by substituting for the item "Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers -" the item "Narcotic substances; the following:";

(lx) by deleting the item "Natalizumab" and the particulars relating to it;

(lxi) by deleting the item "Necitumumab" and the particulars relating to it;

(lxii) by inserting after the item "Nepafenec" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Neratinib	-	All preparations";				

(lxiii) by substituting for the item "Nitric Oxide" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Nitric Oxide	-	Preparations in the form of medicinal gas for therapeutic use	-	-	-	All preparations unless in Group B";

(lxiv) by deleting the item "Nivolumab" and the particulars relating to it;

(lxv) by deleting the item "Obinutuzumab" and the particulars relating to it;

(lxvi) by deleting the item "Ofatumumab" and the particulars relating to it;

(lxvii) by deleting the item "Omalizumab" and the particulars relating to it;

(lxviii) by deleting the item "Palivizumab" and the particulars relating to it;

(lxix) by deleting the item "Panitumumab" and the particulars relating to it;

(lxx) by deleting the item "Pembrolizumab" and the particulars relating to it;

(lxxi) by deleting the item "Pertuzumab" and the particulars relating to it;

(lxxii) by substituting for the item "Phenytoin and other substances structurally derived from hydantoin; their salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Phenytoin and other substances structurally derived from hydantoin; their salts	-	All preparations unless exempted	-	-	-	Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984 containing derivatives of hydantoin";

(lxxiii) by inserting after the item "Phosphorus white, yellow, red or black" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Pibrentasvir	-	All preparations";				

(lxxiv) by deleting the item "Ramucirumab" and the particulars relating to it;

(lxxv) by deleting the item "Ranibizumab" and the particulars relating to it;

(lxxvi) by inserting after the item "Ribavirin" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ribociclib	-	All preparations";				

(lxxvii) by inserting after the item "Riociguat" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ripasudil	-	All preparations";				

(lxxviii) by deleting the item "Rituximab" and the particulars relating to it;

(lxxix) by deleting the item "Secukinumab" and the particulars relating to it;

(lxxx) by inserting after the item "Selexipag" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Semaglutide	-	All preparations				
Semduramicin	-	All preparations";				

(lxxxi) by substituting for the item "Sildenafil; its salts" and the particulars relating to it the following items:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Sildenafil	-	All preparations				
Siltuximab	-	All preparations";				

(lxxxii) by inserting after the item "Simeprevir" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Simoctocog alfa	-	All preparations";				

(lxxxiii) by inserting after the item "Tadalafil" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Tafluprost	-	All preparations";				

(lxxxiv) by deleting the item "Tocilizumab" and the particulars relating to it;

(lxxxv) by deleting the item "Trastuzumab" and the particulars relating to it;

(lxxxvi) by inserting after the item "2, 2, 2-Trichloroethanol; esters of; their salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"3-Trifluoromethylphenylpiperazine (TFMPP)	-	All preparations";				

(lxxxvii) by inserting after the item "Trioxsalen" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Triptorelin	-	All preparations";				

(lxxxviii) by inserting after the item "Udenafil" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Ulinastatin	-	All preparations unless exempted	-	-	-	Naturally occurring ulinastatin";

(lxxxix) by deleting the item "Ustekinumab" and the particulars relating to it;

(xc) by inserting after the item "Vecuronium; its salts" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Velpatasvir	-	All preparations";				

(xci) by deleting the item "Vedolizumab" and the particulars relating to it;

(xcii) by inserting after the item "Vemurafenib" and the particulars relating to it the following item:

Names	*Part I*				*Part II*	*Exempt*
	Group A	*Group B*	*Group C*	*Group D*		
"Venetoclax	-	All preparations"; and				

(xciii) by deleting the item "Zacyclonol; its salts" and the particulars relating to it; and

(b) in the Appendix to the Poisons List—

(i) in the list of **"Analeptics and Central Stimulants:" —**

(A) by inserting after the item "Cathinone (DD)" the item "4-Chloromethcathinone";

(B) by inserting after the item "2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)" the item "Dimethylone";

(C) by inserting after the item "Fluoroamphetamine (4-FA) (DD)" the item "3-Fluoromethcathinone";

(D) by inserting after the item "Leptazol" the item "Lisdexamfetamine";

(E) by inserting after the item "Methiopropamine (MPA)" the item "5-Methoxy-N,N-diisopropyltryptamine";

(F) by inserting after the item "5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD)" the following items:
"5-Methoxy-N,N-methylisopropyltryptamine
4-Methyl-alpha-pyrrolidinobutiophenone
4-Methylbuphedrone";

(G) by inserting after the item "4-Methylethcathinone (4-MEC)" the item "Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)";

(H) by inserting after the item "N-methyl-1-(3, 4-methylenedioxyphenyl)-2-butanamide (DD)" the item "Modafinil"; and

(I) by inserting after the item "Strychnine" the item "3-Trifluoromethylphenylpiperazine (TFMPP)";

(ii) in the list of **"Analgesics including antipyretic and anti-inflammatory agents:"** —

(A) by inserting after the item "Enphenamic acid; its salts" the item "Erenumab"; and

(B) by inserting after the item "Mesalazine" the item "2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)";

(iii) in the list of **"Anti-asthmatics:**" —

(A) by inserting after the item "Bambuterol" the item "Benralizumab"; and

(B) by inserting after the item "Indacaterol" the item "Mepolizumab";

(iv) in the list of **"Antidiabetics:" —**

(A) by inserting after the item "Empagliflozin" the item "Ertugliflozin"; and

(B) by inserting after the item "Saxagliptin" the item "Semaglutide";

(v) in the list of "**Antifungals and Antiprotozoals:**"—

(A) by inserting after the item "Imidocarb" the item "Isavuconazole"; and

(B) by inserting after the item "Secnidazole" the item "Semduramicin";

(vi) in the list of "**Antihistamines:**", by inserting after the item "Cyproheptadine" the item "Desloratadine";

(vii) in the list of "**Antihypertensives:**", by inserting after the item "Lacidipine" the item "Lercanidipine";

(viii) in the list of "**Antineoplastic agents and Immunosuppressants:**"—

(A) by inserting after the item “Abatacept” the item “Abemaciclib”;

(B) by inserting after the item “Afatinib” the item “Alectinib”;

(C) by inserting after the item “Anastrozole” the item “Apalutamide”;

(D) by inserting after the item “Azathioprine; its salts” the item “Baricitinib”;

(E) by inserting after the item “Brentuximab” the following items:

“Brigatinib

Brodalumab”;

(F) by inserting after the item “Cisplatin” the item “Cladribine”;

(G) by inserting after the item “Gemcitabine, its salts” the item “Guselkumab”;

(H) by inserting after the item “Irinotecan; its salts ” the following items:

“Ixazomib

Ixekizumab”;

(I) by inserting after the item “Lomustine; its salts” the item “Lorlatinib”;

(J) by inserting after the item "Necitumumab" the item "Neratinib";

(K) by inserting after the item "Regorafenib" the following items:
"Ribociclib
Risankizumab";

(L) by inserting after the item "Ruxolitinib" the item "Sarilumab";

(M) by inserting after the item "Semustine; its salts" the item "Siltuximab";

(N) by inserting after the item "Trimetrexate" the item "Triptorelin"; and

(O) by inserting after the item "Vemurafenib" the item "Venetoclax";

(ix) in the list of "**Antitubecular agents:**", by inserting after the item "p-Amino salicyclic acid and other substances structurally derived therefrom; their salts; their esters" the item "Bedaquiline";

(x) in the list of "**Antiviral agents:**"—

(A) by inserting after the item "Atazanavir" the item "Baloxavir marboxil";

(B) by inserting after the item "Elbasvir" the item "Elvitegravir";

(C) by inserting after the item "Ganciclovir" the item "Glecaprevir";

(D) by inserting after the item "Ledipasvir" the item "Letermovir";

(E) by inserting after the item "Penciclovir" the item "Pibrentasvir"; and

(F) by inserting after the item "Valaciclovir; its salts" the item "Velpatasvir";

(xi) in the list of "**Hormones:**", by deleting the item "Zacyclonol; its salts";

(xii) in the list of "**Narcotics:**", by substituting for the item "Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); salts of their esters and ethers:" the item "Narcotic substances; the following:";

(xiii) in the list of "**Tranquillisers:**", by inserting after the item "Captodiamine; its salts" the item "Cariprazine";

(xiv) in the list of "**Vasolidators:**", by substituting for the item " Sildenafil; it salts" the item "Sildenafil"; and

(xv) in the list of "**Miscellaneous:**"—

(A) by inserting after the item "Clopidogrel" the item "Cobicistat";

(B) by inserting after the item "Eltrombopag" the item "Emicizumab";

(C) by inserting after the item "Eptifibatide" the item "Erdosteine";

(D) by inserting after the item "Ergot, alkaloids of" the item "Etelcalcetide";

(E) by inserting after the item "Fluorides, alkali; organofluorides" the item "Fluralaner";

(F) by inserting after the item "Glucose" the item "Glutathione";

(G) by inserting after the item "Iomeprol" the item "Iopamidol";

(H) by inserting after the item "Lodoxamide tromethamine" the item "Lonoctocog alfa";

(I) by inserting after the item "Lovastatin" the item "Lubiprostone"

(J) by inserting after the item "Rimonabant" the item "Ripasudil";

(K) by inserting after the item “Silodosin” the item “Simoctocog alfa”;

(L) by inserting after the item “Sumatriptan” the item “Tafluprost”; and

(M) by inserting after the item “L-Tryptophan” the item “Ulinastatin”.

Made 7 August 2020
[KKM.R.600-1/1/56; PN(PU2)172/XVIII]

DATO’ SRI DR. ADHAM BIN BABA
Minister of Health